FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid, Cannabis-Based Investigational Treatment for Chronic Low Back Pain
Cannabis Business Times
The company anticipates a first data read-out in 2027 and, subject to positive results, plans to submit a New Drug Application in 2028 for VER-01, an investigational standardized full-spectrum extract derived from the Cannabis sativa strain DKJ127 L. Its composition includes a defined mixture of cannabinoids, terpenes and other bioactive compounds.